A 23-year-old cisgender man with a CD4 count of 386 cells/mm3 took the antiretroviral regimen efavirenz-tenofovir DF-emtricitabine and did well on this regimen for about 18 months, with persistently undetectable HIV RNA levels. Subsequently, he had a 6-month period of poor adherence and the HIV RNA level increased to 2,320 copies/mL. A genotype is performed and two significant mutations are identified: M184V and K103N. No other mutations are reported.
Which one of the following is TRUE regarding the K103N mutation?
Figure 1. Impact of K103N Mutation on Activity of NNRTI Medications
Source: illustration by David H. Spach, MD
Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Since you are not signed in, your progress won't be saved.
Question Last Updated
September 22nd, 2023
September 22nd, 2023
Steps to Acquire CE for this Question Bank Topic:
1
Answer
Answer all questions
2
Score 80%+
Answer correctly
3
Claim CE
Choose CNE or CME
4
Give Feedback
Complete survey
5